Tojacia 5 mg Tablet

Composition of Tojacia 5 mg Tablet

Tojacia 5 mg Tablet contains Tofacitinib (5mg). It belongs to the Janus kinase (JAK) inhibitor class of medicines.

Uses of Tojacia 5 mg Tablet

• Treatment of moderate to severe rheumatoid arthritis (RA) in adults (especially when response to methotrexate is inadequate/intolerant); may be used alone or with methotrexate/other non-biologic DMARDs. Also used in certain inflammatory conditions as prescribed by a specialist (e.g.
• psoriatic arthritis
• ulcerative colitis) based on clinical judgement and approval status.

Key benefits

• Reduces joint pain and swelling in rheumatoid arthritis
• Improves physical function and quality of life
• Helps control inflammation and disease activity
• May reduce progression of joint damage (with appropriate therapy)

How Tojacia 5 mg Tablet works

Tofacitinib is a Janus kinase (JAK) inhibitor (primarily JAK1/JAK3) that reduces signaling of multiple cytokines involved in inflammation. This decreases immune overactivity and helps reduce joint pain, swelling, and progression of inflammatory damage.

How to take Tojacia 5 mg Tablet

Oral tablet. Take exactly as prescribed by the doctor, usually 5 mg twice daily (or as advised). Can be taken with or without food; swallow whole with water. Do not stop abruptly without medical advice; regular lab monitoring is required.

Take it exactly as your doctor prescribed. Do not change the dose or stop early on your own.

Missed dose and overdose

If you miss a dose

Take it as soon as you remember. If your next dose is almost due, skip the one you missed — never take two doses together to catch up.

If you take too much

An overdose of this medicine can seriously suppress the bone marrow and damage the liver. Do not wait for symptoms to appear — go to the nearest emergency department and take the pack or strip with you.

Side effects of Tojacia 5 mg Tablet

Most side effects of Tojacia are mild and settle as the body adjusts. Reported side effects include:

• Upper respiratory tract infection
• headache
• diarrhea
• nausea
• increased cholesterol
• hypertension
• rash
• herpes zoster (shingles)
• anemia
• neutropenia/low white blood cells
• elevated liver enzymes

Stop the medicine and seek help immediately for a rash, swelling of the face or lips, wheezing or difficulty breathing. Tell your doctor about any side effect that persists or worries you.

Safety advice for Tojacia 5 mg Tablet

Warnings and precautions

Serious risk of infections (including TB, fungal, and opportunistic infections); screen for TB and hepatitis before starting. Increased risk of herpes zoster. May increase risk of blood clots (DVT/PE), major cardiovascular events, and malignancies (including lymphoma and skin cancers), especially in older patients and those with risk factors. Monitor CBC, liver function, lipids; avoid in severe hepatic impairment; dose adjustments may be needed in renal/hepatic impairment. Not recommended with other potent immunosuppressants/biologics. Seek urgent care for fever, persistent cough, shortness of breath, chest pain, leg swelling, or unexplained bruising/bleeding.

Do not take Tojacia if

Not for anyone with a known allergy to this medicine or to any ingredient in the pack. Not for people with an active serious infection, or with severe liver or bone-marrow disease. Several of these medicines must not be used in pregnancy.

Interactions with other medicines

Strong CYP3A4 inhibitors (e.g., ketoconazole) and moderate CYP3A4 + strong CYP2C19 inhibitors (e.g., fluconazole) may increase levels; strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin) may reduce effect. Increased infection risk with biologic DMARDs (e.g., adalimumab, etanercept, infliximab), other immunosuppressants (e.g., azathioprine, cyclosporine, tacrolimus). Live vaccines should be avoided during therapy.

How to store Tojacia 5 mg Tablet

Store at room temperature (below 25°C), protected from moisture and light. Keep in original blister pack and out of reach of children.

Expert advice for Tojacia 5 mg Tablet

Keep every monitoring blood test appointment. Carry a note of the medicine and its schedule, especially for weekly dosing.

Manufacturer and class

Manufacturer:

CIPLA LIMITED

Therapeutic class:

Antirheumatic / Immunomodulator

Drug class:

Janus kinase (JAK) inhibitor